Brought to you by 
Nurix pens $2.3bn collaboration with Gilead; Option exercised
20 Mar 2023
Executive Summary
Nurix Therapeutics Inc. gained another major partner through a new multi-year deal with Gilead Sciences Inc. in which the companies will focus on targeted protein degradation treatments for cancer and other serious diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nurix pens $2.3bn collaboration with Gilead; Option exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice